Clinical trial
Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory…
NCT00358020 · University of Turin, Italy, Other · Completed
Key facts
| NCT number | NCT00358020 |
|---|---|
| Title | Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients |
| Official title | A Phase II, Multi-Center, Open Label Study Of Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients |
| Lead sponsor | University of Turin, Italy, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | THALIDOMIDE, BORTEZOMIB |
| Enrollment | 30 |
| Start date | Nov 1, 2004 |
| Completion | Dec 1, 2008 |
| First posted | Jul 28, 2006 |
| Last update posted | Dec 4, 2006 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: